Will JUPITER Change Statin Use?
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.
You may also be interested in...
Crestor Label Lends Validity To Controversial C-Reactive Protein Test
FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say
Crestor Label Lends Validity To Controversial C-Reactive Protein Test
FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say
Crestor Advisory Meeting Weighs Value Of C-Reactive Protein Risk Marker
In deciding whether to approve AstraZeneca's Crestor (rosuvastatin) for wider use, FDA will need to say what role high sensitive C-reactive protein levels will play in determining who should take the statin as a preventive measure. Until then, the size of Crestor's market opportunity for the pending claim remains somewhat unclear